170 related articles for article (PubMed ID: 15703503)
21. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
Hirsch M; O'donnell J; Olsson A
Int J Cardiol; 2005 Oct; 104(3):251-6. PubMed ID: 16186052
[TBL] [Abstract][Full Text] [Related]
22. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
Sever PS; Poulter NR; Dahlof B; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes G; Mehlsen J; Nieminen MS; O'Brien ET; Ostergren J;
Eur Heart J; 2008 Feb; 29(4):499-508. PubMed ID: 18175773
[TBL] [Abstract][Full Text] [Related]
23. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.
Sever P; Dahlöf B; Poulter N; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen S; Kristinsson A; McInnes G; Mehlsen J; Nieminem M; O'Brien E; Ostergren J;
Eur Heart J; 2006 Dec; 27(24):2982-8. PubMed ID: 17145722
[TBL] [Abstract][Full Text] [Related]
24. Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm.
Collier DJ; Poulter NR; Dahlöf B; Sever PS; Wedel H; Buch J; Caulfield MJ;
J Hypertens; 2011 Mar; 29(3):592-9. PubMed ID: 21297502
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS.
Lafuma A; Colin X; Solesse A
Arch Cardiovasc Dis; 2008 May; 101(5):327-32. PubMed ID: 18656091
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
van Hout BA; Simoons ML
Eur Heart J; 2001 May; 22(9):751-61. PubMed ID: 11350107
[TBL] [Abstract][Full Text] [Related]
28. Lipid lowering in hypertension and heart protection: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study.
Nadar S; Lim HS; Beevers DG; Lip GY
J Hum Hypertens; 2002 Dec; 16(12):815-7. PubMed ID: 12522461
[No Abstract] [Full Text] [Related]
29. Atorvastatin: its clinical role in cerebrovascular prevention.
Gaspardone A; Arca M
Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521
[TBL] [Abstract][Full Text] [Related]
30. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
Gómez-Gerique JA; Casciano R; Stern L; Rejas J
Eur J Health Econ; 2004 Oct; 5(3):278-84. PubMed ID: 15714350
[TBL] [Abstract][Full Text] [Related]
31. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
Arca M
Drugs; 2007; 67 Suppl 1():43-54. PubMed ID: 17910520
[TBL] [Abstract][Full Text] [Related]
32. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Sever PS; Poulter NR; Dahlöf B; Wedel H; Collins R; Beevers G; Caulfield M; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J
Diabetes Care; 2005 May; 28(5):1151-7. PubMed ID: 15855581
[TBL] [Abstract][Full Text] [Related]
33. The value of atorvastatin over the product life cycle in the United States.
Grabner M; Johnson W; Abdulhalim AM; Kuznik A; Mullins CD
Clin Ther; 2011 Oct; 33(10):1433-43. PubMed ID: 21955936
[TBL] [Abstract][Full Text] [Related]
34. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
Nissen SE
Am J Cardiol; 2005 Sep; 96(5A):61F-68F. PubMed ID: 16126025
[TBL] [Abstract][Full Text] [Related]
35. [Cost-effectiveness of atorvastatin for the prevention of coronary disease. An analysis of the ASCOT study].
Szucs TD; Klose G; Düsing R
Dtsch Med Wochenschr; 2004 Jun; 129(25-26):1420-4. PubMed ID: 15213873
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study.
Taylor DC; Pandya A; Thompson D; Chu P; Graff J; Shepherd J; Wenger N; Greten H; Carmena R; Drummond M; Weinstein MC
Eur J Health Econ; 2009 Jul; 10(3):255-65. PubMed ID: 18800232
[TBL] [Abstract][Full Text] [Related]
37. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
Tran YB; Frial T; Miller PS
Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
Miller PS; Smith DG; Jones P
Am J Cardiol; 2005 Jun; 95(11):1314-9. PubMed ID: 15904635
[TBL] [Abstract][Full Text] [Related]
39. Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm.
Brown WV; Moussa M
Curr Opin Lipidol; 2003 Dec; 14(6):593-7. PubMed ID: 14624136
[TBL] [Abstract][Full Text] [Related]
40. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]